AR053561A1 - Compuestos novedosos, isomeros de los mismos o las sales farmaceuticamente aceptables de los mismos como el antagonista del receptor vaniloide y las composiciones farmaceuticas que contienen los mismos - Google Patents
Compuestos novedosos, isomeros de los mismos o las sales farmaceuticamente aceptables de los mismos como el antagonista del receptor vaniloide y las composiciones farmaceuticas que contienen los mismosInfo
- Publication number
- AR053561A1 AR053561A1 ARP060101059A ARP060101059A AR053561A1 AR 053561 A1 AR053561 A1 AR 053561A1 AR P060101059 A ARP060101059 A AR P060101059A AR P060101059 A ARP060101059 A AR P060101059A AR 053561 A1 AR053561 A1 AR 053561A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkoxy
- alkyl
- haloc1
- alkenyl
- phenyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 239000005557 antagonist Substances 0.000 title 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 10
- 125000000217 alkyl group Chemical group 0.000 abstract 9
- 125000003342 alkenyl group Chemical group 0.000 abstract 8
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 7
- 125000004414 alkyl thio group Chemical group 0.000 abstract 6
- 229910052736 halogen Inorganic materials 0.000 abstract 6
- 150000002367 halogens Chemical class 0.000 abstract 6
- -1 C1-5alkyloxy Chemical group 0.000 abstract 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 5
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 5
- 125000004448 alkyl carbonyl group Chemical group 0.000 abstract 4
- 125000004390 alkyl sulfonyl group Chemical group 0.000 abstract 3
- 125000000304 alkynyl group Chemical group 0.000 abstract 3
- 125000001424 substituent group Chemical group 0.000 abstract 3
- 125000003282 alkyl amino group Chemical group 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 abstract 1
- 208000006820 Arthralgia Diseases 0.000 abstract 1
- 206010020751 Hypersensitivity Diseases 0.000 abstract 1
- 208000019695 Migraine disease Diseases 0.000 abstract 1
- 208000028389 Nerve injury Diseases 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 206010040880 Skin irritation Diseases 0.000 abstract 1
- 208000007107 Stomach Ulcer Diseases 0.000 abstract 1
- 102000003566 TRPV1 Human genes 0.000 abstract 1
- 101150016206 Trpv1 gene Proteins 0.000 abstract 1
- 125000003302 alkenyloxy group Chemical group 0.000 abstract 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000032625 disorder of ear Diseases 0.000 abstract 1
- 230000002550 fecal effect Effects 0.000 abstract 1
- 201000005917 gastric ulcer Diseases 0.000 abstract 1
- 125000001188 haloalkyl group Chemical group 0.000 abstract 1
- 208000019622 heart disease Diseases 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 230000009610 hypersensitivity Effects 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 208000002551 irritable bowel syndrome Diseases 0.000 abstract 1
- 206010027599 migraine Diseases 0.000 abstract 1
- 125000002757 morpholinyl group Chemical group 0.000 abstract 1
- 210000004400 mucous membrane Anatomy 0.000 abstract 1
- 230000008764 nerve damage Effects 0.000 abstract 1
- 208000004296 neuralgia Diseases 0.000 abstract 1
- 201000001119 neuropathy Diseases 0.000 abstract 1
- 230000007823 neuropathy Effects 0.000 abstract 1
- 125000004193 piperazinyl group Chemical group 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 239000002464 receptor antagonist Substances 0.000 abstract 1
- 229940044551 receptor antagonist Drugs 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 208000023504 respiratory system disease Diseases 0.000 abstract 1
- 208000017520 skin disease Diseases 0.000 abstract 1
- 230000036556 skin irritation Effects 0.000 abstract 1
- 231100000475 skin irritation Toxicity 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
- 210000003932 urinary bladder Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
- C07C275/20—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
- C07C275/24—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing six-membered aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
- C07C275/18—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of a saturated carbon skeleton containing rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C311/08—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/11—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic unsaturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/62—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/10—Oxygen atoms
- C07D309/12—Oxygen atoms only hydrogen atoms and one oxygen atom directly attached to ring carbon atoms, e.g. tetrahydropyranyl ethers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0803—Compounds with Si-C or Si-Si linkages
- C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Hydrogenated Pyridines (AREA)
- Pyrane Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente se refiere a los compuestos novedosos, los isomeros de los mismos o las sales farmacéuticamente aceptables de los mismos como el antagonista del receptor vaniloide (Receptor Vaniloide 1; VR1; TRPV1), y una composicion farmacéutica que contiene a los mismos. La presente proporciona una composicion farmacéutica para prevenir o tratar una enfermedad tal como dolor, migrana, artralgia, neuralgia, neuropatías, herida en los nervios, skin disorder, hipersensibilidad de la vejiga urinaria, síndrome del intestino irritable, urgencia fecal, a desorden respiratorio, irritacion de la piel, membrana del ojo o mucosa, ulcera duodenal-estomacal, la enfermedad inflamatoria s, ear disease, y heart disease. Reivindicacion 1: Un compuesto de la formula (1), un isomero del mismo, o una sal farmacéuticamente aceptable del mismo en donde: X es NHCH2, CR11=CR12, NH, CHR11CHR12, o C:::C, en donde R11 y R12 son independientemente H, halogeno, alquilo C1-5, alcoxi C1-5, halo C1-5- alquilo o fenilo; R1 es alquenilo C2-5 o alquinilo C2-5; R2 es H, halogeno, nitro, ciano, alquilo C1-5, alcoxi C1-5, haloC1-5-alquilo, alquenilo C2-5, alquinilo C2-5, carboxi, alcoxicarbonilo C1-5, alquiltio C1-5, fenilo, o fenilC1-3alquilo, en donde, cada fenilo puede estar sustituido o no sustituido con uno o más sustituyentes seleccionados de carboxi, alquilo C1-5, halogeno, nitro, alquenilo C2-5, alcoxi C1-5, haloC1-5alquilo, alquilcarbonilo C1-5, alquiltio C1-5, alquilsulfonilo C1-5 y alcoxicarbonilo C1-5; R3 es H, alquilo C1-5, alcoxi C1-5, o haloC1-5alquilo; R4, R5, R6, R7, y R8 son independientemente H, carboxi, alquilo C1-5, nitro, alquenilo C2-5, alcoxi C1-5, alquinilo C2-5, haloC1-5alquilo, alquiltio C1-5, alquilsulfonilo C1-5, alquilcarbonilo C1-5, alcoxicarbonilo C1-5, hidroxi, alqueniloxi C2-5, alcoxi C1-5-alcoxi C1-5, alcoxi C1-5-alcoxiC1-5-alquilo C1-5, alquilpiperazinilo C1-3, piperazinilo C1-5alcoxi, piperidiniloC1-5alcoxi, alcoxi C1-5-alquilamino C1-5, alquilamino C1-7, morfolinilo, morfoliniloC1-5alquiloxi, tetrahidropiraniloxi, fenilo o halogeno, en donde fenilo puede estar sustituido o no sustituido con uno o más sustituyentes seleccionados de carboxi, alquilo C1-5, halogeno, nitro, alquenilo C2-5, alcoxi C1-5, haloC1-5alquilo, alquilcarbonilo C1-5, alquiltio C1-5, alquilsulfonilo C1-5, alcoxicarbonilo C1-5, o piperidiniloxi no sustituido o sustituido con alcoxicarbonilo C1-5, y R9 y 10 son independientemente H, -SO2R13, -SOR13, alquilo C1-5, alcoxi C1-5, haloC1-5alquilo, alquenilo C2-5, alcoxicarbonilo C1-5, alquiltio C1-5, fenilo, o fenilC1-3alquilo, en donde, cada fenilo puede estar sustituido o no sustituido con uno o más sustituyentes seleccionados de carboxi alquilo C1-5, halogeno, nitro, alquenilo C2-5, alcoxi C1-5, haloC1-5alquilo, alquilcarbonilo C1-5, alquiltio C1-5, alquilsulfonilo C1-5 y alcoxicarbonilo C1-5, y R13 es H, amino, alquilo C1-5, alquenilo C2-5, alcoxi C1-5, haloC1-5alquilo, trifluormetilo, fenilo o fenilC1-3alquilo.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20050022986 | 2005-03-19 | ||
US66326905P | 2005-03-21 | 2005-03-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR053561A1 true AR053561A1 (es) | 2007-05-09 |
Family
ID=37023953
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP060101059A AR053561A1 (es) | 2005-03-19 | 2006-03-17 | Compuestos novedosos, isomeros de los mismos o las sales farmaceuticamente aceptables de los mismos como el antagonista del receptor vaniloide y las composiciones farmaceuticas que contienen los mismos |
ARP060101058A AR056943A1 (es) | 2005-03-19 | 2006-03-17 | DERIVADOS DE AMIDAS, ISoMEROS DE LOS MISMOS O LAS SALES FARMACÉUTICAMENTE ACEPTABLES DE LOS MISMOS COMO EL ANTAGONISTA DEL RECEPTOR VANILOIDE Y LAS COMPOSICIONES FARMACÉUTICAS QUE CONTIENEN LOS MISMOS |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP060101058A AR056943A1 (es) | 2005-03-19 | 2006-03-17 | DERIVADOS DE AMIDAS, ISoMEROS DE LOS MISMOS O LAS SALES FARMACÉUTICAMENTE ACEPTABLES DE LOS MISMOS COMO EL ANTAGONISTA DEL RECEPTOR VANILOIDE Y LAS COMPOSICIONES FARMACÉUTICAS QUE CONTIENEN LOS MISMOS |
Country Status (14)
Country | Link |
---|---|
US (2) | US7763657B2 (es) |
EP (2) | EP1861357B1 (es) |
JP (2) | JP5159604B2 (es) |
KR (2) | KR101304981B1 (es) |
AR (2) | AR053561A1 (es) |
AU (2) | AU2006225496A1 (es) |
BR (2) | BRPI0608714A2 (es) |
CA (2) | CA2601871A1 (es) |
EA (2) | EA200702020A1 (es) |
IL (2) | IL185891A0 (es) |
MX (2) | MX2007011466A (es) |
NO (2) | NO20075354L (es) |
TW (2) | TW200716523A (es) |
WO (2) | WO2006101318A1 (es) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2601871A1 (en) | 2005-03-19 | 2006-09-28 | Amorepacific Corporation | Novel compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same |
AU2007277519B2 (en) | 2006-07-27 | 2011-12-22 | Amorepacific Corporation | Novel compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same |
DE102007017884A1 (de) | 2007-04-13 | 2008-10-16 | Grünethal GmbH | Neue Vanilloid-Rezeptor Liganden und ihre Verwendung zur Herstellung von Arzneimitteln |
US20110160279A1 (en) * | 2007-08-13 | 2011-06-30 | Board Of Trustees Of Southern Illinois University | METHODS FOR TREATMENT AND PREVENTION OF OTOTOXICITY BY siRNA |
CN101925575B (zh) | 2008-01-28 | 2014-06-18 | 株式会社爱茉莉太平洋 | 作为香草酸受体拮抗剂的化合物、其异构体或其药物学可接受的盐、及包含这些化合物的药物组合物 |
EP2484664B1 (en) * | 2008-05-07 | 2013-09-04 | Dainippon Sumitomo Pharma Co., Ltd. | Cyclic amine-1-carboxylic acid ester derivative and pharmaceutical composition containing the same |
WO2010002209A2 (en) | 2008-07-02 | 2010-01-07 | Amorepacific Corporation | Novel compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist and pharmaceutical compositions containing the same |
ES2673301T3 (es) * | 2010-11-03 | 2018-06-21 | University Of Hawaii | Métodos y composiciones para la prevención y el tratamiento de la hipertrofia cardíaca |
AR085509A1 (es) | 2011-03-09 | 2013-10-09 | Bayer Cropscience Ag | Indol- y bencimidazolcarboxamidas como insecticidas y acaricidas |
US9012450B2 (en) | 2011-12-28 | 2015-04-21 | Global Blood Therapeutics, Inc. | Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation |
CN104135859B (zh) | 2011-12-28 | 2017-06-27 | 全球血液疗法公司 | 取代的苯甲醛化合物及其用于增加组织氧合的方法 |
CN104884426A (zh) * | 2012-12-28 | 2015-09-02 | 日本脏器制药株式会社 | 肉桂酰胺衍生物 |
PE20160078A1 (es) | 2013-03-15 | 2016-03-02 | Global Blood Therapeutics Inc | Compuestos y sus usos para modular la hemoglobina |
US8952171B2 (en) | 2013-03-15 | 2015-02-10 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
AP2015008721A0 (en) | 2013-03-15 | 2015-09-30 | Global Blood Therapeutics Inc | Compounds and uses thereof for the modulation of hemoglobin |
MY183637A (en) | 2013-03-15 | 2021-03-04 | Global Blood Therapeutics Inc | Compounds and uses thereof for the modulation of hemoglobin |
PT3102208T (pt) | 2014-02-07 | 2021-04-05 | Global Blood Therapeutics Inc | Polimorfos cristalinos da base livre de 2-hidroxi-6-((2-(1-isopropil-1h-pirazol-5-il)piridin-3 il)metoxi)benzaldeído |
TW201731509A (zh) | 2015-12-04 | 2017-09-16 | 全球血液治療公司 | 針對2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之劑量方案 |
US11014884B2 (en) | 2018-10-01 | 2021-05-25 | Global Blood Therapeutics, Inc. | Modulators of hemoglobin |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6087254A (ja) * | 1983-10-19 | 1985-05-16 | Japan Carlit Co Ltd:The | 新規尿素化合物及びそれを含有する除草剤 |
WO2000050387A1 (en) * | 1999-02-22 | 2000-08-31 | Pacific Corporation | Vanilloid analogues containing resiniferatoxin pharmacophores as potent vanilloid receptor agonists and analgesics, compositions and uses thereof |
MXPA03001535A (es) | 2000-08-21 | 2004-12-13 | Pacific Corp | Derivados de tiourea novedosos y las composiciones farmaceuticas que contienen los mismos. |
WO2002016319A1 (en) * | 2000-08-21 | 2002-02-28 | Pacific Corporation | Novel thiourea compounds and the pharmaceutical compositions containing the same |
GB0105895D0 (en) * | 2001-03-09 | 2001-04-25 | Smithkline Beecham Plc | Novel compounds |
JP2005518371A (ja) | 2001-12-10 | 2005-06-23 | アムジエン・インコーポレーテツド | バニロイド受容体リガンド及び治療に於けるこれらの使用 |
CN1307150C (zh) | 2002-05-08 | 2007-03-28 | 拜耳医药保健股份公司 | 羟基四氢-萘基脲衍生物 |
CL2003001415A1 (es) * | 2002-07-12 | 2005-01-07 | Janssen Pharmaceutica Nv | Compuestos d derivados de naftil, quinolinil e isoquinolinil urea; composicion farmaceutica; y uso en el tratamiento y prevencion de condiciones de dolor y en el sibndrome del colon irritable y condiciones asociadas. |
KR100707123B1 (ko) * | 2003-07-02 | 2007-04-16 | 그뤼넨탈 게엠베하 | 바닐로이드 수용체의 길항제로서 강력한 진통효과를나타내는 4-(메틸설포닐아미노)페닐 동족체 및 이를함유하는 약학적 조성물 |
BRPI0513286A (pt) * | 2004-07-15 | 2008-05-06 | Japan Tobacco Inc | compostos de benzamida condensada e inibidores de atividade de receptor vanilóide subtipo (vr1), suas composições farmacêuticas, pacote comercial, fármaco e respectivos usos |
ITMI20042042A1 (it) * | 2004-10-26 | 2005-01-26 | Pharmeste Srl | Derivati solfonammidici antagonisti del recettore dei vanilloidi trpv1 |
EP1858865B1 (en) * | 2005-03-10 | 2009-09-16 | Pfizer Inc. | Substituted n-sulfonylaminophenylethyl-2-phenoxy acetamide compounds |
CA2601871A1 (en) | 2005-03-19 | 2006-09-28 | Amorepacific Corporation | Novel compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same |
-
2006
- 2006-03-15 CA CA002601871A patent/CA2601871A1/en not_active Abandoned
- 2006-03-15 KR KR1020077024002A patent/KR101304981B1/ko active IP Right Grant
- 2006-03-15 EP EP06716379.0A patent/EP1861357B1/en active Active
- 2006-03-15 WO PCT/KR2006/000929 patent/WO2006101318A1/en active Application Filing
- 2006-03-15 AU AU2006225496A patent/AU2006225496A1/en not_active Abandoned
- 2006-03-15 JP JP2008502895A patent/JP5159604B2/ja active Active
- 2006-03-15 EA EA200702020A patent/EA200702020A1/ru unknown
- 2006-03-15 BR BRPI0608714-0A patent/BRPI0608714A2/pt not_active Application Discontinuation
- 2006-03-15 US US11/909,136 patent/US7763657B2/en active Active
- 2006-03-15 MX MX2007011466A patent/MX2007011466A/es not_active Application Discontinuation
- 2006-03-17 US US11/909,144 patent/US7960584B2/en active Active
- 2006-03-17 AU AU2006225434A patent/AU2006225434A1/en not_active Abandoned
- 2006-03-17 BR BRPI0608624-1A patent/BRPI0608624A2/pt not_active Application Discontinuation
- 2006-03-17 WO PCT/KR2006/000988 patent/WO2006101321A1/en active Application Filing
- 2006-03-17 MX MX2007011205A patent/MX2007011205A/es not_active Application Discontinuation
- 2006-03-17 EA EA200702021A patent/EA200702021A1/ru unknown
- 2006-03-17 TW TW095109337A patent/TW200716523A/zh unknown
- 2006-03-17 EP EP06716438A patent/EP1861358A4/en not_active Withdrawn
- 2006-03-17 KR KR1020077024004A patent/KR101304979B1/ko active IP Right Grant
- 2006-03-17 AR ARP060101059A patent/AR053561A1/es unknown
- 2006-03-17 JP JP2008502896A patent/JP5064374B2/ja active Active
- 2006-03-17 CA CA002601873A patent/CA2601873A1/en not_active Abandoned
- 2006-03-17 TW TW095109137A patent/TW200716522A/zh unknown
- 2006-03-17 AR ARP060101058A patent/AR056943A1/es unknown
-
2007
- 2007-09-11 IL IL185891A patent/IL185891A0/en unknown
- 2007-09-11 IL IL185892A patent/IL185892A0/en unknown
- 2007-10-18 NO NO20075354A patent/NO20075354L/no not_active Application Discontinuation
- 2007-10-18 NO NO20075353A patent/NO20075353L/no not_active Application Discontinuation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR053561A1 (es) | Compuestos novedosos, isomeros de los mismos o las sales farmaceuticamente aceptables de los mismos como el antagonista del receptor vaniloide y las composiciones farmaceuticas que contienen los mismos | |
AR063211A1 (es) | Derivados de 3-(piridin-3-il)acrilamida y 3-(piridin-3-il)propionamida, un metodo para su preparacion, una composicion farmaceutica que los comprende y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades asociadas con el receptor vaniloide. | |
CY1108908T1 (el) | Ενωσεις κινολινονης - καρβοξαμιδης ως αγωνιστες υποδοχεων 5-ητ4 | |
JP2011520792A5 (es) | ||
PE20091099A1 (es) | Derivados de aminobenzamida como agentes utiles para controlar parasitos animales | |
RU2010148570A (ru) | Циклические ингибиторы 11бета-гидроксистероид-дегидрогеназы 1 | |
AR052938A1 (es) | Compuestos de n-sulfonilaminofeniletil-2-fenoxiacetamida sustituidos, composiciones farmaceuticas que los comprenden y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por el receptor vr1 | |
WO2007071632A3 (en) | 2-pyridin-2-yl-quinazoline derivatives as potassium channel modulating agents for the treatment of respiratory diseases | |
EA200700099A1 (ru) | Производные пиридина | |
AR069490A1 (es) | Agonistas de los receptores de glucocorticoides | |
PE20060691A1 (es) | Serinamidas sustituidas por benzoilo | |
PE20090694A1 (es) | Compuestos moduladores de sirtuinas | |
PE20060150A1 (es) | Antagonistas de cgrp seleccionados, composiciones farmaceuticas y procedimiento para su preparacion | |
EA200702200A1 (ru) | Дигидротиенопиримидины для лечения воспалительных заболеваний | |
DK1697371T3 (da) | Azabicykliske heterocykliske forbindelser som cannabinoidreceptormodulatorer | |
PA8547901A1 (es) | Derivados de 4-piperacinilindol con afinidad receptora de 5-ht6 | |
PE20060640A1 (es) | Derivados del acido alcanoico arilcicloalquil-sustituidos y procedimientos para su preparacion | |
RU2009109159A (ru) | Трансдермальное применение триазинов для борьбы с инфекциями кокцидий | |
PE20211275A1 (es) | Compuestos heterociclicos antihelminticos | |
EA200702612A1 (ru) | Соединения бензимидазолкарбоксамида в качестве агонистов рецепторов 5-нт | |
PE20081160A1 (es) | Arilsulfonil-pirrolidinas como inhibidores 5-ht6 | |
PE20120217A1 (es) | Derivados de carbamatos de alquil-heterociclos, su preparacion y su aplicacion en terapeutica | |
PE20080929A1 (es) | Metodos para el tratamiento de la depresion | |
AR070930A1 (es) | Derivados de pirrolidinilo y tiofeno, composiciones farmaceuticas que los contienen y usos de los mismos para el tratamiento de enfermedades asociadas con inhibidores de reabsorcion de monoaminas,tales como trastornos depresivos y ansioliticos, entre otros. | |
PE20070797A1 (es) | Compuestos de indanil- y tetrahidronaftil-amino-tiourea para combatir pestes animales |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |